UBS raised the firm’s price target on Solventum (SOLV) to $79 from $77 and keeps a Neutral rating on the shares. Solventum delivered strong Q3 results and proactively addressed 2026 margin concerns with a new $500M long-term cost savings plan, the analyst tells investors in a research note. While initial benefits may be modest, projected 2026 adjusted net income and EPS growth have been raised to 6%, supported by better-than-expected revenue trends, UBS says.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SOLV:
- Cautious Outlook on Solventum Corporation Amid Cost-Saving Initiatives and Tariff Concerns
- Solventum’s Earnings Call Highlights Growth and Optimism
- Solventum Corporation: Strong Q3 Results Overshadowed by Growth Concerns and Transformation Costs
- Early notable gainers among liquid option names on November 7th
- Solventum price target raised to $98 from $94 at Piper Sandler